Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: "James E. Bradner" Clear advanced filters

  • Inhibition of growth stimulatory pathways has emerged as a major focus of targeted cancer drug development. New insights regarding potent, transient inhibition of cell signaling may challenge the dogma of medicinal chemistry and clinical trial design.

    • James E Bradner
    News & Views
    Nature Chemical Biology
    Volume: 5, P: 144-145

  • Deletion of the TP53 gene, an event seen in colorectal cancers, often occurs with co-deletion of a gene that encodes an enzyme subunit governing gene transcription. This creates a vulnerability ripe for therapeutic development. See Letter p.697

    • James E. Bradner
    News & Views
    Nature
    Volume: 520, P: 626-627

  • This review summarizes the state of the art in chemical probes targeting molecular processes operating at the chromatin interface in cancer cells. It seeks to provide a chemical toolbox for use by scientists to dissect epigenetic vulnerabilities of tumour biology.

    • Jake Shortt
    • Christopher J. Ott
    • James E. Bradner
    Reviews
    Nature Reviews Cancer
    Volume: 17, P: 160-183